On the need of a two-tier system for evaluating drugs intended for long-term administration.
D000014:Abnormalities, Drug-Induced; D000818:Animals; D001011:Aorta / Q000378:metabolism; D001923:Brain Chemistry / Q000187:drug effects; D003276:Contraceptives, Oral / Q000009:adverse effects / Q000592:standards*; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008111:Liver Function Tests; D008540:Meiosis / Q000187:drug effects; D009641:Norethynodrel / Q000009:adverse effects; D010060:Ovulation / Q000187:drug effects; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000592:standards*; D010902:Pituitary Gland / Q000187:drug effects; D010908:Pituitary Hormones, Anterior / Q000378:metabolism; D011247:Pregnancy; D011374:Progesterone / Q000009:adverse effects; D051381:Rats; D013997:Time Factors
D003276:Contraceptives, Oral; D008055:Lipids; D004364:Pharmaceutical Preparations; D010908:Pituitary Hormones, Anterior; D011374:Progesterone; D009641:Norethynodrel